BTIG analyst Ryan Zimmerman maintained a Buy rating on NuVasive (NUVA) yesterday and set a price target of $65. The company’s shares closed yesterday at $57.76.
According to TipRanks.com, Zimmerman is a top 100 analyst with an average return of 43.1% and a 68.3% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Integra Lifesciences, and OrthoPediatrics Corp.
NuVasive has an analyst consensus of Moderate Buy, with a price target consensus of $63.
See today’s analyst top recommended stocks >>
Based on NuVasive’s latest earnings release for the quarter ending March 31, the company reported a quarterly net profit of $9.39 million. In comparison, last year the company had a GAAP net loss of $27.13 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
NuVasive, Inc. engages in the development of minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. It offers cervical and spine fusion surgery, cervical plating, and posterior fixation products. The company was founded by Alexis V. Lukianov on July 21, 1997 and is headquartered in San Diego, CA.